Talimogene laherparepvec: overview, combination therapy and current practices.

ABSTRACT: Talimogene laherparepvec (T-VEC, Imlygic^®, Amgen, CA, USA) is an oncolytic herpes simplex type 1 virus used as intralesional therapy for unresectable metastatic melanoma in a cutaneous, subcutaneous or nodal location. Talimogene laherparepvec selectively replicates within and lyses tumor cells while producing granulocyte macrophage colony-stimulating factor, which may promote an immune mediated antitumor response. The US FDA approved T-VEC in late 2015 following Phase I-III trials that demonstrated safety and efficacy. Future directions for T-VEC include combination therapies with other systemic immunotherapies such as anti-CTLA-4 antibody and anti-PD-1 drugs. Current National Comprehensive Cancer Network (NCCN) practice guidelines have added T-VEC as a primary treatment for sta

SUBMITTER: O'Donoghue C 

PROVIDER: S-EPMC6094674 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature